Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
483.07
812.27
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
REGN
stock under the Base Case scenario is
759.83
USD.
Compared to the current market price of 733.04 USD,
Regeneron Pharmaceuticals Inc
is
Undervalued by 4%.
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Regeneron Pharmaceuticals Inc.
Fundamental Analysis
REGN Profitability Score
Profitability Due Diligence
Score
REGN Solvency Score
Solvency Due Diligence
Score
Select up to 3 indicators:
Select up to 3 indicators:
Regeneron’s overreliance on Eylea for a significant portion of its revenue poses a major risk, especially as new anti-VEGF therapies and biosimilars could challenge its market share in retinal diseases and pressure pricing.
The company’s R&D pipeline, though robust, demands high and constant levels of investment, raising concerns about the potential for expensive clinical failures and delayed payoffs that could weigh on profitability.
Partnership dynamics with Sanofi, including profit-sharing agreements for core products like Dupixent, may limit Regeneron’s autonomy on strategic decisions while constricting potential upside from certain therapies.
Despite Eylea’s looming patent expiry, potential label expansions for Dupixent and newer pipeline candidates like pozelimab could diversify revenue sources and provide steady earnings growth.
Regeneron’s proprietary VelociSuite technology platform offers a competitive edge in developing next-generation antibody-based therapies, fueling its strong track record of innovation and drug discovery success.
With multiple late-stage trials in immunology and oncology, Regeneron’s high R&D spend and existing collaborations may translate into meaningful long-term returns if a few key candidates gain regulatory approval.
Revenue & Expenses Breakdown
Regeneron Pharmaceuticals Inc
Balance Sheet Decomposition
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Free Cash Flow Analysis
Regeneron Pharmaceuticals Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Regeneron Pharmaceuticals Inc
Wall St
Price Targets
REGN Price Targets Summary
Regeneron Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
REGN
is 838.03 USD
with a low forecast of 636.3 USD and a high forecast of 1 109.85 USD.
Dividends
Current shareholder yield for
REGN is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
REGN
stock under the Base Case scenario is
759.83
USD.
Compared to the current market price of 733.04 USD,
Regeneron Pharmaceuticals Inc
is
Undervalued by 4%.